ApoE4 lipid-carrying state changes metabolism and inflammatory signalling in human microglia
Published in Brain/Neurology, Immunology, Journals.
Publication date: October 13, 2026.
A study first published on October 11 in Alzheimer’s & Dementia, and highlighted by CU Anschutz on October 12, examines how the lipid-carrying state of ApoE affects human microglia, the brain’s immune cells. Researchers compared lipid-free and lipid-bound ApoE3 and ApoE4 in laboratory experiments.
ApoE4-treated cells developed fewer but larger lipid droplets and more fragmented mitochondria than ApoE3-treated cells. These effects were stronger with lipid-bound ApoE4. Proteomic analysis also detected a type I interferon response to lipid-free ApoE, intensified by the ApoE4 form.
The findings suggest two distinguishable cellular responses: lipid-bound ApoE4 changes metabolic organisation, while lipid-free ApoE4 promotes inflammatory signalling. This may help researchers investigate how APOE4-associated Alzheimer’s risk relates to microglial function.
Evidence limits: This was a laboratory study, not a patient trial. It does not establish that these changes cause Alzheimer’s in people or demonstrate a treatment. Carrying APOE4 increases risk but does not mean a person will develop the disease.
Sources: Shiferaw et al., Alzheimer’s & Dementia, October 11, 2026; CU Anschutz announcement, October 12, 2026.